Two immunotherapy drugs for relapsed follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two immunotherapy drugs (mosunetuzumab and tislelizumab) for people with follicular lymphoma that has returned or not responded to earlier treatments. The goal is to see if this combination can help control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have follicular lymphoma that came back or did not respond to at least 2 previous treatments.
- One of your past treatments must have included a CD20-targeting drug like rituximab.
- You are in relatively good health (able to do daily activities) and your blood, liver, and kidney tests are within acceptable ranges.
- You do not have an active infection, serious heart problems, or lymphoma in the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Mosunetuzumab for people with follicular lymphoma that has come back or stopped responding after at least two previous treatments. It is available through a compassionate use program for those who have no other options.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
This study tests a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if this two-drug approach can help shrink tumors and control the disease.
This study tests two new drugs combined together to treat follicular lymphoma (a slow-growing blood cancer). The trial enrolls patients who have never been treated, those with limited disease who want active treatment, and those whose cancer came back or didn't respond to prior therapy.
This trial tests two new drugs, pirtobrutinib and mosunetuzumab, for people with follicular lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help control the cancer.
This Phase 2 study tests mosunetuzumab, an antibody treatment, for people with follicular lymphoma that relapsed (came back) or progressed soon after first treatment. It may help shrink the cancer again after early relapse or lack of response to standard therapy.
Hear when a new Relapsed/Refractory Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.